Indeed, we detected that enforced elevation of ROS in CLL cells activated AXL and its downstream targets FGFR22, AKT and ERK1/2, but not IGF1Rβ or c-MET. The gene discussed is MAPK3; the disease is B-cell chronic lymphocytic leukemia.